Drug
Bay 3401016
Bay 3401016: highest development phase Phase 2, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| BAY 3401016 NCT07211685 | Phase 2 | Alport Syndrome |
Latest
No recent events.
Follow Bay 3401016 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.